Clinical Trials Logo

Angelman Syndrome clinical trials

View clinical trials related to Angelman Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05127226 Active, not recruiting - Angelman Syndrome Clinical Trials

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.

NCT ID: NCT04428281 Active, not recruiting - Angelman Syndrome Clinical Trials

A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome

Start date: August 19, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I, multicenter, non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study with an LTE part. The objective of the study is to investigate the safety, tolerability, PK and PD of RO7248824 in participants administered IT with AS. Two linked sets of dose escalation cohorts are planned based on two different age groups, namely participants with AS aged ≥ 5 to ≤ 12 years in cohorts A1 to A4 (with at least 2 participants ≤ 8 years old in each cohort) and AS participants aged ≥ 1 to ≤ 4 years in cohorts B1 to B5. The two sets of cohorts will be run in parallel, with each cohort A1-A4 preceding and gating the linked cohort B1-B5 (e.g., A1 precedes B1).

NCT ID: NCT04259281 Active, not recruiting - Angelman Syndrome Clinical Trials

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Start date: February 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (AS).